Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

First Clinical Milestone Achieved in Collaboration between AbCheck and Lilly

GlobeNewswire January 31, 2017

Affimed Announces Closing of Public Offering of Common Stock

GlobeNewswire January 25, 2017

15 Biggest Mid-Day Losers For Friday

Benzinga.com  January 20, 2017

Mid-Day Market Update: Crude Oil Up 2.8%; Bristol-Myers Squibb Shares Slide After Opdivo Decision

Benzinga.com  January 20, 2017

Mid-Morning Market Update: Markets Open Higher; General Electric Revenue Misses Views

Benzinga.com  January 20, 2017

Affimed Announces Pricing of Public Offering of Common Stock

GlobeNewswire January 20, 2017

Affimed Announces Proposed Public Offering of Common Stock

GlobeNewswire January 19, 2017

Affimed Provides Update on NK-Cell Immuno-Oncology Platform

GlobeNewswire January 11, 2017

Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration

GlobeNewswire January 4, 2017

Affimed Presents New Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH

GlobeNewswire December 6, 2016

Affimed to Present at the Jefferies 2016 London Healthcare Conference

GlobeNewswire November 9, 2016

Affimed to Present Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH

GlobeNewswire November 8, 2016

Affimed Reports Financial Results for Third Quarter 2016

GlobeNewswire November 2, 2016

Affimed to Present at the Credit Suisse 25th Annual Healthcare Conference

GlobeNewswire October 31, 2016

Affimed Announces Third Quarter 2016 Financial Results and Corporate Update Conference Call

GlobeNewswire October 26, 2016

Affimed Presents Preclinical Data on Lead Candidate AFM13 at the Annual Meeting of the Society for Natural Immunity

GlobeNewswire October 4, 2016

Affimed to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

GlobeNewswire September 22, 2016

Affimed to Present at Upcoming Investor Conferences

GlobeNewswire September 1, 2016

Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update

GlobeNewswire August 10, 2016

Affimed Announces Second Quarter 2016 Financial Results and Corporate Update Conference Call

GlobeNewswire August 3, 2016